Bud BilanichSuccess Coach
Liz KaneImpactful Strategy
Paul TheisenPatient Acquisition
Suma Ramadas, PhDMedical Affairs
Stacey GandlerBrand Nourishment
Matt TurnerPatient Affordability
David LinetskyPoint-of-Care Marketing
Daniel SontupeMarket Access
Frank BurrellScientific Storytelling
Matthew DurhamOmnidynamic Marketing
Amy GilesIncreasing Engagement
Pat PurcellMeeting Engagement
Brenda SnowAuthentic Patient Voice
Joey CohenMedication Adherence
YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email
